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Abstract Hypertension is one of the major risk factors for
atrial fibrillation which in turn is the most prevalent concom-
itant condition in hypertensive patients. While both these
pathological conditions are independent risk factors for stroke,
the association of hypertension and atrial fibrillation increases
the incidence of disabling strokes. Moreover, documented or
silent atrial fibrillation doubles the rate of cardiovascular
death. Lowering blood pressure is strongly recommended,
particularly for primary stroke prevention. However, a rela-
tively small percentage of hypertensive patients still achieve
the recommended blood pressure goals. The management of
atrial fibrillation with respect to stroke prevention is changing.
New oral anticoagulants represent a major advancement in
long-term anticoagulation therapy in non valvular atrial fibril-
lation. They have several benefits over warfarin, including
improved adherence to the anticoagulation therapy. This is
an important issue since non-adherence to stroke prevention
medications is a risk factor for first and recurrent strokes.
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Introduction
Stroke, a recurrent and, to a large degree, preventable disorder,
represents the third-common cause of death worldwide.
Despite evidence that the incidence of stroke has slightly de-
clined in the western countries and the rate of in-hospital mor-
tality has decreased in stroke patients over the past four de-
cades [1], one-third of the stroke patients still die in the first
year, and half of them become permanently disabled [1, 2]. It
has been reported that the world-wide prevalence of stroke is
about 15million cases per year, and in the USA alone there are
approximately 800,000 new patients per year suffering a
stroke. The incidence of stroke in developing countries is in-
creasing. Moreover, recurrent strokes still account for 25 % to
30 % of all strokes representing unsuccessful secondary pre-
vention [3–5]. Therefore, both primary and secondary preven-
tion is critical in limiting the burden of cerebrovascular disease
worldwide. The purpose of primary stroke prevention is the
management of the modifiable cardiovascular risk factors and
the clinical conditions that predispose an individual to stroke
occurrence, whereas secondary prevention is aimed to addi-
tionally target several different pathological conditions that
predispose an individual to the occurrence of recurrent stroke.
In a large standardized case–control study performed in 22
countries worldwide over three years of follow-up, ten modi-
fiable risk factors (including hypertension, smoking, abdomi-
nal obesity, diet, lack of physical activity, diabetes, alcohol
intake, psychosocial stress, depression, cardiac causes, and
lipid abnormalities) were associated with 90 % of all strokes.
Among these risk factors, hypertension, smoking, waist-to-hip
ratio, diet, and alcohol intake were significantly associated
with intracerebral haemorrhagic stroke [6]. Evidence-based
guidelines focused on primary and secondary prevention sug-
gest that those modifiable risk factors should be targeted in
clinical practice in order to reduce the health consequences
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and socio-economic burden of stroke [7]. For the secondary
prevention of recurrent stroke risk-stratification according to
the presence of diabetes, hyperlipidemia, atrial fibrillation,
current tobacco smoking, and hypertension should be per-
formed principally during the hospitalization for acute stroke.
Therefore, any effort should be recommended to modify these
risk factors in order to reduce the risk of recurrent stroke [7].
This is particularly true for hypertension which is responsi-
ble of about 50 % of strokes. Lowering blood pressure in hy-
pertensive patients is strongly recommended, particularly for
primary stroke prevention [7–9]. Furthermore, hypertension is
also a distinct and major risk factor for the occurrence of atrial
fibrillation (AF) [7–9]. In fact, it is a component of several
prognostic scoring systems, including CHA2DS2 VASc scores
in AF patients for stroke prevention.
AF is a serious risk factor for cardiovascular patients since
it is associated with a high risk of cardiovascular complica-
tions, hospitalization, and death. Most importantly, AF in-
creases five fold the risk of stroke and worsens the clinical
outcome in patients who experienced stroke, in view of the
fact that AF is associatedwith increased incidence of disabling
strokes, particularly when associated to other cardiovascular
risk factors, including hypertension [7, 9].
In this review we will focus on the current evidence of
hypertension and AF management for stroke prevention.
Hypertension and Stroke
Hypertension is one of the major and independent cardiovas-
cular risk factors and contributes to the development of target
organ damage and cardiovascular and cerebrovascular events.
Both systolic and diastolic hypertension are associated with
the occurrence of both primary and recurrent strokes [8, 9, 10,
11••], mainly when blood pressure remains poorly controlled
[12, 13•]. Moreover, elevated systolic blood pressure upon
hospital discharge after a stroke represents a strong predictor
of early recurrence of further cerebrovascular events [14].
Notably, a correlation has been reported between the preva-
lence of hypertension and the mortality for stroke [15], which
is significantly higher after a recurrent stroke compared to a
primary stroke [16].
Over the past forty years, randomized controlled trials
(most of them versus placebo) have provided evidence that
lowering blood pressure with different classes of antihyper-
tensive drugs results in risk reduction for major clinical car-
diovascular outcomes, including fatal and nonfatal stroke in
hypertensive individuals [8, 17]. This is strikingly evident for
primary stroke prevention of any type [18]. In particular, a
recent meta-analysis including more than 50,000 patients has
shown that lowering blood pressure provided similar relative
protection for all levels of baseline cardiovascular risk,
although progressively greater absolute risk reductions for
higher levels of baseline risk were observed [19••].
Post-hoc analysis of randomized data suggest that the re-
duction of fatal and non fatal cardiovascular outcomes are, in
part, due to the regression of the alterations in the target organ
damage, such as the structural alterations induced by hyper-
tension in the cardiovascular system (i.e., left ventricular hy-
pertrophy and remodelling, fibrosis, vascular remodelling, in-
tima-media-thickness, and urinary protein excretion) [20, 21].
Undoubtedly, reducing blood pressure is the most impor-
tant step in stroke prevention [22], even for patients at low-to-
moderate cardiovascular risk and/or with baseline blood pres-
sure in the range of grade 1 hypertension [23–25], although a
large part of supporting evidence is provided bymeta-analyses
including a relatively small number of patients [23, 24].
However, less clear is the approach for lowering blood pres-
sure in patients after a stroke. This is due to the paucity of
published trials specifically focused on the management of
hypertension for recurrent stroke prevention [11••, 12, 13•].
Nonetheless, as long as blood pressure is successfully re-
duced, all antihypertensive regimens are acceptable for stroke
prevention [22], mainly in patients who had a previous stroke.
Meta-analyses of randomized controlled trials have reported
about a 40 % reduction in recurrent stroke risk with blood
pressure lowering regimens [11••, 12, 26]. This has been
shown without a clear J-curve effect, although this latter find-
ing is not consistent in all the trials [27–31].
The ESH/ESC guidelines suggest treating hypertensive pa-
tients with a history of cerebrovascular events with a recom-
mended therapeutic goal of <140 mmHg [8]. This target may
be considered to be higher, to some extent, in elderly hyper-
tensives with previous stroke or transient ischemic attack
(TIA) [8]. Importantly, in high-risk patients, the antihyperten-
sive regimen should be carefully monitored in order to avoid
the variability of intra-individual blood pressure measurement
at follow-up visits. Indeed, this is associated with the in-
creased incidence of stroke [32]. The effects of antihyperten-
sive drugs on blood pressure variability are dose-dependent
and are more evident for a specific class of drugs such as
calcium antagonists, mainly when used in combination with
other antihypertensive drugs [33]. Interestingly, in a large-
scale observational study, it has been shown that the recom-
mended antihypertensive treatment achieved blood pressure
control in a limited number of hypertensive patients seen by
general practitioners (GPs) [34]. This highlights the discrep-
ancies between clinical practice and guideline recommenda-
tions, suggesting that any effort should be provided in order to
fill this gap in clinical practice. Indeed, an increased awareness
of stroke risk factors by GPs is associated with improved
blood pressure control in the ten-year estimated risk of stroke
[35].
Meta-analyses and meta-regression analyses suggested that
some differences in stroke prevention may exist among the
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different antihypertensive classes of drugs. Beta-blockers may
be inferior to calcium antagonists and renin-angiotensin sys-
tem (RAS) blockers for stroke prevention [36, 37]. This is
possibly due to the lesser effect of beta-blockers in reducing
central systolic blood pressure and pulse pressure [38, 39].
Calcium antagonists may have a greater effectiveness on
stroke prevention [40–42]. Thismay be due tomore consistent
blood pressure control obtained with this class of drugs al-
though a less defined protective effect on the brain circulation
could be also advocated [8].
Among RAS blockers, angiotenisn receptor blockers
(ARBs) have shown greater cerebrovascular protective effects
in clinical trials and meta-analyses compared to different clas-
ses of drugs [43, 44]. This is mainly due to the selective
blockade of the RAS, which plays a central role in the devel-
opment and maintenance of the structural and functional alter-
ations in the cardiovascular system, typically associated with
stroke occurrence [45–47]. In theMOSES trial (Morbidity and
Mortality After Stroke, Eprosartan Compared With
Nitrendipine for Secondary Prevention), ARB did demon-
strate the ability to reduce stroke recurrence compared to cal-
cium channel blockers, though in a limited population sample
[43]. ACE inhibitors did not show similar consistent protec-
tive effects; rather, in some trials, ACE inhibitors performed
inferiorly to other classes of drugs in preventing stroke
[40–42], unless they were used in combination therapy. In
secondary stroke prevention in the PROGRESS trial
(Perindopril Protection Against Recurrent Stroke Study),
ACE inhibitors in combination with diuretics showed a sig-
nificant reduction of cerebrovascular events [48]. However,
this was apparently due mostly to the blood pressure lowering
effect of the diuretic indapamide. In fact, combination therapy
using a diuretic and another different class of drugs has shown
to be successful in stroke prevention, particularly in the elderly
and in higher cardiovascular risk patients [45, 49–51]. The use
of combination therapy is quite common in clinical practice,
since about 70–80 % of treated hypertensive patients may
require combination therapy (at least two classes of drugs) in
order to achieve the recommended blood pressure goals, par-
ticularly in high cardiovascular risk patients. Despite this ev-
idence and the recommendations, a relatively small percent-
age of hypertensive patients (about 30–40 %) still achieve
recommended blood pressure goals in clinical trials [52],
and more than 50 % of patients still receive monotherapy.
Atrial Fibrillation and Stroke
AF is one of the most common cardiac arrhythmias, with a
relatively high prevalence in the general population (1–2 %)
[53]. AF increases the risk of cardiovascular events, including
stroke, since AF is present in about 15 % of patients who
suffer cerebrovascular events. Interestingly, the risk of stroke
is similar in both paroxysmal AF and permanent or persistent
AF [54•]; as also, there is evidence that subclinical or silent
AF might contribute to 25 % of unexplained strokes [54•, 55].
Documented AF or subclinical or silent AF doubles the rate of
cardiovascular death [56].
Several cardiovascular risk factors are associated and pre-
dispose an individual to the occurrence of AF. Among those
risk factors, age, hypertension, and diabetes correlate to the
development of AF [6, 57–59]. These risk factors are also
associated with thrombembolic complications of AF, mainly
stroke. Several risk models are available for risk stratification
and prevention of thromboembolism in patients with AF [7,
9]. In all of these models, hypertension is present and repre-
sents an important risk factor. The CHA2DS2-Vasc-score is a
simple clinical approach to assess the individual risk for
thromboembolic complications in patients with diagnosed
AF. In those patients with a score >1, a net benefit from anti-
thrombotic treatment in primary and secondary prevention has
been shown [7, 9]. Nevertheless, AF may be silent and, there-
fore, unrecognized in about 40 % of AF patients [54•, 60•].
Time and duration of AF per day represent additional risk
factors for cerebrovascular events, since it has been shown
that one hour in daily AF time resulted in increased risk of
stroke by about 3 % [61•]. Patients with silent AF are, indeed,
at high risk for stroke which may occur in more than 30 % of
patients [54•, 60•]. It is likely those patients do not receive
anticoagulants, and this may increase the risk of stroke [62•],
yet the benefits of antithrombotic treatment in patients with
subclinical AF remain to be further studied [63]. Thus, mon-
itoring AF episodes with electrocardiography (ECG) record-
ing devices may become crucial and this approach should be
considered in select patients [7, 9, 64].
In relation to the risk score, most patients with AF should
receive anticoagulant therapy to reduce the risk of stroke. It
has been shown that the relative risk of ischemic stroke was
decreased by 67 %, and the risk of all-cause mortality was
reduced by 27 % by using oral anticoagulants [65].
Antithrombotic treatment with the vitamin K antagonist
(VKA) warfarin is effective in either primary or secondary
prevention of thromboembolic events in AF patients.
However, quite recently, novel oral anticoagulants (NOACs)
that do not require international normalized ratio (INR) mon-
itoring have been introducedwith promising results in patients
with non valvular AF [66]. NOACs include direct thrombin
inhibitors, dabigatran, factor Xa inhibitors, rivaroxaban,
apixaban, and edoxaban; they have been shown to be non-
inferior and sometimes superior to warfarin [7, 9, 67], and
have reduced all-cause mortality in different clinical trials
[67]. The selection of an anticoagulant drug should be indi-
vidualized based on renal and hepatic function, potential drug
interaction, patient preference, tolerability, previous
anticoagulation effectiveness and safety, as well as cost [66,
67]. Anticoagulants are associated with a risk of bleeding
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complications. Therefore, the possibility of anticoagulation
should be weighted against the bleeding risk of the patient.
However, NOACs, compared with VKAs, are associated with
less intracranial hemorrhage and are generally preferred over
VKAs [66, 67].
It should be noted that, despite the evidence that long-term
oral anticoagulation for secondary stroke prevention in AF is
highly effective, it is frequently not started or discontinued in
clinical practice. In a recent prospective cohort study the non-
adherence to oral anticoagulation in stroke patients resulted
from fear of potential complications (such as bleeding) or
inconvenience of regular international normalized ratio mea-
surements and physicians’ concerns regarding functional sta-
tus of patients [68•]. Nevertheless, there is evidence that per-
sistence with therapy may be better with NOACs than with
warfarin [67, 68•, 69]. It is important to note that in most
studies addressing the efficacy of VKA or NOACs in patients
with AF, blood pressure changes and the role of antihyperten-
sive therapy are underreported or even not analyzed [70••].
Hypertension and Atrial Fibrillation
High blood pressure is an established risk factor for AF which
in turn is the most prevalent concomitant condition in hyper-
tensive patients [7, 9]. AF greatly enhances the disability and
mortality in hypertensive subjects [71–73]. Blood pressure
values even in the high normal range are associated with the
development of this arrhythmia [74]. AF may be associated
with different functional and structural alterations induced by
hypertension in the cardiovascular system, including structur-
al changes in the heart (i.e., left atrium enlargement), fibrosis,
heart failure, neurohormonal activation, and atherosclerosis
[45–47]. In particular, a pooled analysis of data from AFFI
RM (The Atrial Fibrillation Follow-up Investigation of
Rhythm Management) and AF-CHF (Atrial Fibrillation and
Congestive Heart Failure) patients with paroxysmal or persis-
tent AF showed that systolic blood pressure is an important
determinant of recurrent AF burden only in patients with left
ventricular dysfunction (LVEF≤40 %) but not in those with
preserved ventricular function [75•].
In hypertensive patients, AF is a common cause of cardio-
vascular complications, including stroke [76, 77]; thus, pre-
vention of new episodes of AF is warranted, particularly in
hypertensive patients [77]. Antihypertensive treatment may
contribute to a reduction of risk, and it seems that some classes
of drugs are superior to others in the prevention of new-onset
AF and stroke prevention [67]. This is related to the concom-
itant clinical conditions and to the distinctive property of a
specific drug in reversing structural cardiac damage caused
by hypertension [78, 79].
In particular, ARBs seems to be more effective in
preventing the first occurrence of AF than other drugs such
as beta-blockers and calcium antagonists in hypertensive pa-
tients with structural heart disease (left ventricular hypertro-
phy or dysfunction) [80–84] and no history of AF [81, 85, 86].
However clinical trials have shown that ARBs were less able
to prevent recurrences of paroxysmal or persistent AF [87,
88•, 89], and also did not improve survival in patients with
established AF. Thus, the beneficial effects of ARBs may be
limited to the prevention of incident AF in patients with hy-
pertension and structural heart disease [88•] and no history of
AF [8, 67]. This may be due to the beneficial effects on atrial
stretch, interstitial fibrosis, inflammation, and structural re-
modelling. On the other hand, it should be noted that while
ARBs may be helpful in prevention of AF in patients with
early or reversible cardiac structural changes [45, 80], they
may be much less effective in patients with more advanced
or heterogeneous cardiac disease [87].
Nevertheless, a recent meta-analysis indicates that
telmisartan seems to be more effective than other antihyper-
tensive drugs in preventing AF recurrences among hyperten-
sive patients with paroxysmal AF, beyond blood pressure re-
duction [90•]. Several mechanisms are postulated, including
strong binding affinity to angiotensin II type 1 receptors, the
specific property to block potassium channels involved in the
ultra-rapid delayed rectifier currents in atrial myocytes [91]
and an effect in facilitating parasympathetic activity as well
as reducing QT dispersion [92]. These findings have not been
confirmed in high-risk patients with established atherosclerot-
ic disease [93, 94].
In patients with AF and a high ventricular rate, beta-
blockers and non-dihydropyridine calcium antagonists are
recommended [7, 9]; also, beta-blockers and mineralocorti-
coid antagonists may prevent atrial fibrillation, particularly
in patients with heart failure [95, 96].
Hypertensive patients with AF should be assessed for the
risk of thromboembolism by the above mentioned scores (i.e.,
CHA2DS2-Vasc-score) [7, 9]. Where indicated by the score,
those patients should receive oral anticoagulation therapy [7,
9, 65]. In patients receiving anticoagulation therapy, effective
blood pressure control should be warranted in order to reduce
bleeding events [97••].
Conclusion
Hypertension is the most common cardiovascular disorder
and AF is the most common clinically relevant arrhythmia.
Hypertension predisposes an individual to the development of
AF and these conditions frequently coexist. Their prevalence
increases rapidly with aging and is associated with the occur-
rence of both primary and recurrent cerebrovascular events.
Stroke constitutes a clinical and socio-economic burden, due
to the high prevalence of disability after the first year follow-
ing an acute event. Stroke risk can be substantially reduced by
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using the medical measures that have been proven in many
randomized trials. Hence, prescription of evidenced-based
stroke prevention medications in AF and/or hypertensisve pa-
tients is mandatory. However, it is still a challenge to translate
the efficacy of the interventions reported in clinical trials into
everyday clinical practice. Blood pressure control is extremely
relevant for primary and secondary cardiovascular and cere-
brovascular prevention, although only 30–40 % of patients
with arterial hypertension achieve the recommended blood
pressure goals in clinical trials [34, 35, 52]. Therefore, efforts
should be made to improve blood pressure control, especially
through the use of effective and well tolerated combination
therapies in hypertensive patients, particularly those with high
cardiovascular risk profiles.
The management of AF with respect to stroke prevention is
changing. The antithrombotic therapy is challenging due to the
overlap of ischemic stroke predictors such as the
CHA2DS2 VASc score and major bleeding scores (i.e.,
HAS BLED score) [7–9, 66]. Currently, NOACs represent a
major advance in long-term anticoagulation therapy in non
valvular AF and have many benefits over warfarin; not second-
ly, this class of drugs is characterized by improved adherence to
anticoagulation therapy. This is an extremely important issue
since non-adherence to stroke prevention medications is a risk
factor for first and recurrent strokes [98•]. Finally, the future
management of AF should combine prevention and
personalised treatment of AF that results in an effective predic-
tion of AF and mortality and morbidity prevention.
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